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| INTRODUC TI ON
Neuroendocrine tumors (NET) that primarily arise from the gastrointestinal tract, lungs, pancreas, liver, and thymus, are considered extremely rare; however, recently, their incidence has begun to rapidly increase. 1 Specifically, the epidemiological database established by the Surveillance, Epidemiology and End Results (SEER) study in the USA has reported that the incidence of NET increased fivefold from 1.09 to 5.25 per 100 000 individuals between 1973 and 2014. 1 Furthermore, 3379 patients were treated for pancreatic neuroendocrine tumors (pNET) in 2010 in Japan, which represented a 1.2-fold increase in the incidence from 2005 to 2010, 2 with an additional approximately 8088 patients having been treated for gastrointestinal neuroendocrine tumors (GI-NET), representing an approximate 1.8-fold increase since 2005 in Japan. Furthermore, midgut NET accounts for 30%-60% of all gastrointestinal NET in the Americas and European countries, yet is extremely rare in Asian countries. [1] [2] [3] When NET cells were first isolated, they were described as enterochromaffin cells and, thus, were classified as benign or as having low malignant potential. However, many NET show metastatic properties and, therefore, NET have been reclassified as malignant.
In 2010, the World Health Organization (WHO) defined four types of NET, namely NET G1, NET G2, NET G3 and mixed adenoneuroendocrine carcinoma (MANEC), according to the proliferative capacity of the cells and the ratios (%) of cells that were found to establish exocrine phenotypes. 4 NET G1, G2 and G3 are classified as gastroenteropancreatic NET (GEP-NET) based on the number of cells engaged in active mitotic division and the Ki-67 labeling index.
Specifically, NET G3, also known as neuroendocrine cell carcinoma (NEC), is defined as containing >20 mitotic cells in 10 high-power fields or as having a Ki-67 labeling index >20%. Recently, in the most recent WHO classification of 2019, NEC has been divided into smallcell and large-cell types. 5 However, another subgroup of NET has been described that is not included in the WHO classification system, although it is associated with NET G3 and has a well-differentiated morphology. 6, 7 Hence, Velayoudom-Cephise et al proposed a new classification of NET G3 based on a combination of morphological characteristics and tumor grading. 6 The histological appearance of NEC is solid or trabecular, with a high mitotic index, and is immunohistochemically positive for chromogranin A (CgA), synaptophysin, CD56 (neural cell adhesion molecules: NCAM) and/or somatostatin receptor type 2 (SSTR2).
Clinically, NEC is among the most aggressive types of tumor, with high metastatic capacity and resistance to chemotherapy resulting in poor prognoses. Median overall survival of patients with colonic NET G3 is ~8 months. 8 Colorectal malignant tumors with a solid or alveolar structure are rare and include poorly differentiated adenocarcinoma, medullary carcinoma and NEC. 9,10 However, the histopathological and clinical characteristics of colorectal NEC and NEC from other sources have not been fully investigated because of the paucity of clinical sources and established cell lines. NEC cell lines from the ascending colon are very rarely established, with HROC57 the only new line reported in 2018. 11 We have, therefore, established a novel NEC cell line derived from an ascending colon tumor, and have transplanted the cells into nude mice. We also determined that this cell line formed spheres in vitro that expressed high levels of a specific cancer stem cell (CSC) marker. Analysis of this newly established NEC cell line derived from the midgut should serve to elucidate the mechanisms of proliferation and metastasis of colorectal NEC and inform the development of effective platforms for the testing of antitumor drugs. 
| MATERIAL S AND ME THODS

| Original tumor processing
| Primary in vitro culture
The tumor was rinsed with sterile PBS supplemented with benzylpenicillin potassium (100 U/mL) and kanamycin sulfate and cut into 1-mm fragments. The fragments were suspended in 20% FBS (Nichirei Bioscience Inc.) and seeded into 60-mm primary tissue culture dishes that were incubated in a humidified incubator at 37°C in 5% CO 2 for 4 hours. The dishes were coated with 3-4 mL RPMI-1640 medium (Thermo Fisher Scientific) containing 15% FBS and antibiotics. The growth media was replaced every 3 days. When fibroblast cell growth was observed, an essentially pure tumor cell population was extracted by differential trypsinization followed by 5-6 passages. The new cell line was cultured for more than 60 passages in the RPMI-1640 medium containing 10% FBS and named SS-2.
| Short tandem repeat and amelogenin analyses of SS-2 cells
Genomic DNA was extracted from SS-2 cells using the Wizard SV Genomic DNA Purification System (Promega) according to manufacturer's instructions. DNA concentration was quantified using a Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific). Short tandem repeat (STR) and amelogenin expression levels were then analyzed using the GenePrint 10 System (Promega), as described by the manufacturer.
| Immunohistochemical analysis
Paraffin-embedded tissue sections (3.5 µm) and cells cultured on for CgA or synaptophysin was found to be positive in more than 50% of the tumor cells, a diagnosis of NEC was made in accordance with guidelines established in a previous report. 13 
| Heterotopic transplantation in vivo
| Immunoblotting
Cells were lysed with 50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 5 mmol/L EDTA, and 1% Triton X-100 (Nacalai Tesque Inc.), containing protease and phosphatase inhibitor cocktails. Lysates were separated by SDS-PAGE and then transferred onto PVDF membranes (Merck Millipore). After blocking, the membranes were incubated with the following primary antibodies: mouse monoclonal anti-INSM1 (sc-271408; Santa Cruz Biotechnology), polyclonal Anti-Chromogranin A (ab45179; Abcam), mouse monoclonal Anti-Synaptophysin (713831; Nichirei Biosciences Inc.), and mouse monoclonal Anti-β-Actin (A5316;
Sigma-Aldrich). Membranes were incubated with the appropriate peroxidase-conjugated secondary antibodies (Cell Signaling Technology), washed, and developed with ECL Prime reagent (GE Healthcare).
| Transfection of siRNA targeting INSM1
We 
| HT-29-Luc and Caco-2 cells
Conventional colorectal cancer cell lines, namely, HT-29-Luc (JCRB Cell Bank) and Caco-2 (Riken BRC Cell Bank) were cultured in McCoy's 5A and RPMI-1640 media, respectively. Both medias were supplemented with 10% FBS and placed in a humidified incubator at 37°C in 5% CO 2 atmosphere.
| Sphere formation and qRT-PCR analyses of cancer stem cell markers
We seeded SS-2, HT-29-Luc and Caco-2 cells (1.0 × 10 4 /well) in 100-mm, ultra-low attachment plates containing serum-free media supplemented with 10 ng/mL recombinant human basic fibroblast growth factor (bFGF; ReproCell Inc., 10 ng/mL) and epidermal growth factor (EGF; R&D Systems, 20 ng/mL) as 
| Fluorescence-activated cell sorting analysis and cell sorting
Cells were harvested and dissociated as previously described 16, 17 using Accutase cell detachment solution (Merck Millipore).
Dissociated single cells were incubated with rabbit polyclonal anti- Each section was examined with a transmission electron microscope (TEM, H-7500; Hitachi High-Technologies).
| Transmission electron microscopy
| Drug resistance assays
Cells (3.0 × 10 3 /well) were plated in 96-well plates with growth medium. Each anticancer drug was given at the indicated concentration after 1 day and cell growth rates were measured by ATP assays after 4 days using the CellTiter-Glo 2.0 Assay (Promega) according to the manufacturer's protocol. Cell viability was calculated as the percentage of luminescent cells in drug-treated wells relative to non-treated control wells.
| Statistical analyses
Data were statistically analyzed using Easy R (EZR; Saitama Medical Center, Jichi Medical University), which is a graphical interface for determination of R (The R Foundation for Statistical Computing), and is a modified version of R Commander designed to add functions frequently used in biostatistics. 18 Continuous variables were analyzed using Student's t tests. Values with P < .05 were considered statistically significant.
| RE SULTS
| Characteristics of NEC in the ascending colon
Histological findings of cells derived from the resected ascending colon tumor showed solid proliferation without gland-like structures or keratinization present. Moreover, the tumor cells had round to oval nuclei with high nuclear-cytoplasmic (N/C) ratios ( Figure 1A and inset panel). Ki-67 labeling index was determined to be 65% in the preoperative biopsy specimens ( Figure 1B inset) and >20% in the surgically resected tumor tissues ( Figure 1B) . We next sought to establish a differential diagnosis for the tumor by immunohistochemical analysis.
Results showed that tumor cells stained positive for CgA ( Figure 1C) and synaptophysin ( Figure 1D ). Furthermore, TEM analysis showed a large number of neuroendocrine granules (80-200 nm in diameter) in the cytoplasm of the tumor cells ( Figure 2A ). Desmosomes were also observed at the tumor cell membrane (Figure 2B, arrows) . This tumor was, therefore, diagnosed as NEC rather than poorly differentiated adenocarcinoma or medullary carcinoma. 
| Establishment of the NEC cell line, SS-2
The novel NEC cell line derived from the NEC tumor in the ascending colon appeared histologically to contain small, round cells that were in direct contact with each other and that showed high N/C ratios ( Figure 3A, 3) . Additionally, the cells stained positive for CgA and synaptophysin ( Figure 3C, 3 , respectively). Through TEM analysis we also observed that neuroendocrine granules ( Figure 3E) and desmosomes (arrows) were present in the cells. These findings show that the cells maintained morphological and immunohistochemical features associated with NEC, thus confirming that they were NEC cells derived from the ascending colon. That the SS-2 cells originated from a human female was confirmed by amelogenin analysis. We subsequently named the newly defined cell line SS-2. Table 2 describes the major features of this cell line including STR analysis.
| Heterotopic transplantation of SS-2 into nude mice
We assessed tumorigenicity by s.c. injecting SS-2 cells into the flanks of Balb/c nude mice. The SS-2 cells were observed to form solid tumors consisting of small, round cells that had histological features similar to those of the original NEC tissues obtained from the ascending colon tumor ( Figure 4A ). These cells were negative for CgA and stained weakly for synaptophysin ( Figure 4B, 4, insets) .
Furthermore, the Ki-67 labeling index of the tumor cells was determined to be ~100%, but the stromal cells, including lymphocytes, were negative for Ki-67 ( Figure 4D , inset).
| SS-2 cells express INSM-1
INSM-1 regulates the expression of neuroendocrine markers, such
as CgA and synaptophysin. 19 INSM-1 was localized in the nuclei of surgically resected tumors ( Figure 5A) . A single band of ~58 kDa, Figure 5D ).
| Ability of SS-2 cells to form spheres and express CSC markers
We analyzed the ability of SS-2 cells to form spheres in ultra-low attachment plates to confirm the presence of characteristic CSC markers. The SS-2 cells were observed to form round to oval colonies under adherent culturing conditions ( Figure 6A, inset) , whereas floating, grape-like spheres were formed in the ultra-low attachment plates. These results suggest that the spheres contained CSC markers ( Figure 6B, inset) . Moreover, the floating spheres from SS-2 cells expressed higher levels of CD133 mRNA (P < .05), which is a CSC marker, compared to the same cells cultured under adherent conditions ( Figure 7A ). Conversely, the expression levels of CD166 (P = .26), CD24 (P = .46) and CD44 (P = .73) mRNA were not significantly different between spherical and adherent SS-2 cells. Further, FACS analysis confirmed the higher expression of CD133 in floating spheres compared to adherent cells ( Figure 7B ). Sphere formation was also found to significantly impact the expression of CD24 and CD44 mRNA in conventional colon cancer cell lines such as HT-29-Luc and Caco-2 cells, ( Figure 7A ). In contrast, CD133 mRNA expression did not significantly differ between spherical and adherent cells in these alternative cell lines.
| Susceptibility of SS-2 cells to anticancer drugs
To compare the effect of commonly used anticolorectal cancer drugs to SS-2 cells and conventional colorectal cancer cells, we carried out cell viability assays. After the addition of oxaliplatin and fluorouracil (5-FU), cell viabilities were higher in SS-2 cells than in Caco-2 cells, except for in 100 μmol/L oxaliplatin (Figure 8 ). Neuroendocrine carcinoma tumors show high proliferative capacities, with a median Ki-67 labeling index of 80%. 23 In our study patient, the NEC originated from the midgut (ascending colon) and
| D ISCUSS I ON
the Ki-67 labeling index was determined to be 20%-100% in the preoperative biopsy, resected tumor tissues, and in tumors that were implanted into nude mice.
In addition, the reported ratios for distant metastasis in NEC, NET G1/G2 and midgut NEC are 32.3%, 2.7%, and 28.6%, respectively. 2 Currently, somatostatin receptor analogues octreotide and lanreotide are used to treat NET G1, whereas well-differentiated NET (NET G1/G2) in the pancreas is treated with streptozotocin (STZ) and 5-FU, or temozolomide (TEM) and capecitabine (CAP), or everolimus and sunitinib. 3 Treatment with everolimus, specifically, has F I G U R E 7 Expression of cancer stem cell (CSC) markers in SS-2 spheres. A, Findings from qRT-PCR analysis show that spheres formed by SS-2 cells expressed higher levels of CD133 compared to cells cultured in adherent conditions. Expression of CD166, CD24 and CD44 mRNA did not differ significantly between the spheres and adherent SS-2 cells. *P < .05, † P < .01. B, Expression of CD133 in SS-2 cells as determined by flow cytometric analysis. More CD133+ cells were evident among spheres compared to cells cultured in adherent conditions. Representative results are shown. Gating strategy represents CD133+ cells. Right panel shows CD133 expression as mean fluorescence intensity (MFI) been associated with significant improvement in progression-free survival (PFS) of patients with progressive lung or gastrointestinal NET. 24 Moreover, the findings of a recent phase III trial reported that peptide receptor radionuclide therapy (PRRT) using 177 Lu-Dotatate is effective in midgut NET. 25 A common regimen for treatment of primary NEC G3 consists of cisplatin with etoposide. 3 Alternatively, platinum-based chemotherapy drugs are proven to be effective against NEC, yet of limited value against NET G3. 23 In our experiments, oxaliplatin and 5-FU were not effective against SS-2 cells relative to Caco-2 in vitro. As our SS-2 cell line maintained high proliferative capacity, as well as the characteristic immunohistochemical features associated with the original tumor following transplantation into nude mice, it has the potential to be effectively used to study not only NEC growth, invasiveness and metastatic mechanisms but also the effects of these anti-NEC drugs in vivo. To better understand malignant potential and drug resistance, further studies involving the orthotopic implantation of SS-2 cells should be carried out in the near future.
In addition, patient-derived xenografts (PDX) may be effective for clarification of the biological action of NEC and the effectiveness of anticancer drugs.
Within CSC of NET, the SRC, ERK, AKT, and mTOR pathways are upregulated; thus, anti-SRC therapy has been shown to reduce tumor size in vivo. 26 Furthermore, Nanog, OCT4, SOX-2, LGR5, CD133, CD24, CD29, ALDH1, ESA/EpCAM, CD44, CD166, and CD26 are the primary CSC markers associated with conventional colorectal cancer. 27, 28 The present study found that SS-2 cells form spheres that express high levels of specific CSC markers, suggesting that this cell line expresses certain features of spheres, including pluripotency, self-regeneration, and tumorigenicity. These functions contribute to the initiation and metastasis of cancers and participate in generating resistance to chemotherapy and radiation. 29, 30 Spheres generated in cultures of SS-2 cells were found to express high levels of CD133. Moreover, CD166, CD24, and CD44 were not differently expressed between spheres produced by NEC compared to conventional colorectal cancers. These results suggest that CD133 is one of specific CSC markers of SS-2 cells. As CSC are considered to be novel therapeutic targets for cancers, 31 
